BRAF V600E

BRAF codon 600 point mutation p.V600E detected by sequencing, PCR or mutation-specific immunohistochemistry; used as a predictive marker for BRAF/MEK inhibitor therapy across melanoma, thyroid, colorectal, lung and other cancers.

CI-BIO-00000018BRAF graph →NCIt C98342 Tumor-agnostic · 4 approval rows

Also calledp.V600E · BRAF V600E-mutant · c.1799T>A

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug + indication textRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Trametinib US FDA · May 29, 2013 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (24)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	37	31	6	—	1 / 21 / 6 / 8 / 1
Melanoma	31	29	2	—	0 / 19 / 2 / 10 / 0
Thyroid Gland Papillary Carcinoma	12	3	8

Derived

Drugs with predictive evidence (29)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	45	36	9	A	34 / 9	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +12
DabrafenibSmall Molecule	22	19	3	A	18 / 4	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
TrametinibSmall Molecule	20	19	1	A	18 / 0	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
CetuximabMonoclonal Antibody	12	6	6	A	6 / 5	Malignant Colorectal Neoplasm
PanitumumabMonoclonal Antibody	9	6	3	B	4 / 2	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	6	3	3	B	3 / 3	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	4	3	1	B	1 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
CobimetinibSmall Molecule	3	3	—	B	3 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
OxaliplatinSmall Molecule	2	—	2	B	0 / 2	Malignant Colorectal Neoplasm
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
SorafenibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
TovorafenibSmall Molecule	1	1	—	A	1 / 0	Childhood Low Grade Glioma
MEK Inhibitor RO4987655	1	—	1	B	—	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (92)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 92 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600E45
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (364)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Capecitabine	US FDA	—	Efficacy supplement 2011-02-05 (see label)	approved	Feb 5, 2011	openfda
Capecitabine	US FDA	—	Efficacy supplement 2005-06-15 (see label)	approved	Jun 15, 2005	openfda
Capecitabine	US FDA	—	Efficacy supplement 2001-09-07 (see label)	approved	Sep 7, 2001	openfda
Capecitabine	US FDA	—	Efficacy supplement 2001-04-30 (see label)	approved	Apr 30, 2001

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (473)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 247 recruiting · 84 active phase 3 · 2,296 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 301–350 of 473 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05183984	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer(NIRVANA-1)	recruiting	Phase 2	390	ARCAGY/ GINECO GROUPOTHER	6	Apr 13, 2026	clinicaltrials
NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	recruiting	Phase 1	6	City of Hope Medical CenterOTHER	1	Apr 8, 2026	clinicaltrials
NCT04516447	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR)	recruiting	Phase 1	172	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY	7	Apr 7, 2026	clinicaltrials
NCT07506109	A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer	recruiting	Phase 2	49	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Apr 7, 2026	clinicaltrials
NCT04938583	Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer	active not recruiting	Phase 1 / Phase 2	54	CanariaBio Inc.INDUSTRY	1	Apr 6, 2026	clinicaltrials
NCT05785741	A Study of DB-1310 in Advanced/Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	1,000	DualityBio Inc.INDUSTRY	2	Apr 6, 2026	clinicaltrials
NCT03678883	9-ING-41 in Patients With Advanced Cancers	active not recruiting	Phase 2	350	Actuate Therapeutics Inc.INDUSTRY	7	Apr 3, 2026	clinicaltrials
NCT07001618	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer(IMMUNOLIFE2)	recruiting	Phase 2	162	Gustave Roussy, Cancer Campus, Grand ParisOTHER	1	Apr 3, 2026	clinicaltrials
NCT05733598	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	recruiting	Phase 2	60	Replimune, Inc.INDUSTRY	1	Apr 2, 2026	clinicaltrials
NCT02873962	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	active not recruiting	Phase 2	72	Dana-Farber Cancer InstituteOTHER	1	Apr 1, 2026	clinicaltrials
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR)	recruiting	Phase 2	720	Canadian Cancer Trials GroupNETWORK	1	Mar 27, 2026	clinicaltrials
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	recruiting	Phase 2	60	Roswell Park Cancer InstituteOTHER	1	Mar 23, 2026	clinicaltrials
NCT06497985	A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients	recruiting	Phase 3	430	Chipscreen Biosciences, Ltd.INDUSTRY	1	Mar 19, 2026	clinicaltrials
NCT05101070	S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001)	recruiting	Phase 1 / Phase 2	282	ShionogiINDUSTRY	2	Mar 18, 2026	clinicaltrials
NCT06804824	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	recruiting	Phase 1	220	Vividion Therapeutics, Inc.INDUSTRY	2	Mar 18, 2026	clinicaltrials
NCT05194995	JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation	active not recruiting	Phase 1 / Phase 2	48	Allist Pharmaceuticals, Inc.INDUSTRY	1	Mar 16, 2026	clinicaltrials
NCT04417621	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	active not recruiting	Phase 2	134	Novartis PharmaceuticalsINDUSTRY	12	Mar 12, 2026	clinicaltrials
NCT04333706	A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)(EMPOWER)	recruiting	Phase 1 / Phase 2	65	University of Southern CaliforniaOTHER	1	Mar 10, 2026	clinicaltrials
NCT05116189	Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	active not recruiting	Phase 3	643	Merck Sharp & Dohme LLCINDUSTRY	25	Mar 9, 2026	clinicaltrials
NCT05846867	A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	170	AkesoINDUSTRY	1	Mar 4, 2026	clinicaltrials
NCT06951503	AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer	recruiting	Phase 3	560	AkesoINDUSTRY	1	Mar 4, 2026	clinicaltrials
NCT04094688	Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer(SOLARIS)	active not recruiting	Phase 3	455	Alliance for Clinical Trials in OncologyOTHER	2	Mar 3, 2026	clinicaltrials
NCT02721459	XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	active not recruiting	Phase 1	26	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Mar 2, 2026	clinicaltrials
NCT06346067	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	active not recruiting	Phase 3	78	Erasca, Inc.INDUSTRY	9	Feb 27, 2026	clinicaltrials
NCT04430738	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	active not recruiting	Phase 2	40	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	2	Feb 24, 2026	clinicaltrials
NCT04666272	Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection	active not recruiting	—	78	Novartis PharmaceuticalsINDUSTRY	1	Feb 19, 2026	clinicaltrials
NCT07063212	A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)	recruiting	Phase 2	40	Memorial Sloan Kettering Cancer CenterOTHER	1	Feb 19, 2026	clinicaltrials
NCT05171660	Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer	active not recruiting	Phase 3	446	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Feb 17, 2026	clinicaltrials
NCT07407465	Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA)	recruiting	Phase 2	42	Gruppo Oncologico del Nord-OvestOTHER	4	Feb 17, 2026	clinicaltrials
NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	Phase 1	30	Rina PlattnerOTHER	1	Feb 13, 2026	clinicaltrials
NCT02152631	A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER)	active not recruiting	Phase 3	453	Eli Lilly and CompanyINDUSTRY	21	Feb 6, 2026	clinicaltrials
NCT07391566	LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation	not yet recruiting	Phase 1 / Phase 2	99	Luye Pharma Group Ltd.INDUSTRY	1	Feb 6, 2026	clinicaltrials
NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	active not recruiting	Early Phase 1	14	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Feb 5, 2026	clinicaltrials
NCT06268015	Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo)	active not recruiting	Phase 2	16	Nicholas DeVito, MDOTHER	1	Feb 5, 2026	clinicaltrials
NCT07389265	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM)	recruiting	Phase 3	480	University of Campania Luigi VanvitelliOTHER	2	Feb 5, 2026	clinicaltrials
NCT06697197	A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	413	Bristol-Myers SquibbINDUSTRY	9	Feb 3, 2026	clinicaltrials
NCT06440850	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation	recruiting	Phase 2	21	City of Hope Medical CenterOTHER	1	Feb 2, 2026	clinicaltrials
NCT04854668	A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer	active not recruiting	Phase 3	748	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Jan 30, 2026	clinicaltrials
NCT06208657	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	recruiting	Phase 1 / Phase 2	90	Australian & New Zealand Children's Haematology/Oncology GroupOTHER	2	Jan 28, 2026	clinicaltrials
NCT07370818	To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer	not yet recruiting	Phase 2	81	Onconic Therapeutics Inc.INDUSTRY	1	Jan 27, 2026	clinicaltrials
NCT04137107	Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer	active not recruiting	Phase 2 / Phase 3	220	Alliance for Clinical Trials in OncologyOTHER	2	Jan 26, 2026	clinicaltrials
NCT05601973	Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung)	active not recruiting	Phase 2	60	ETOP IBCSG Partners FoundationNETWORK	6	Jan 21, 2026	clinicaltrials
NCT02411448	A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY)	active not recruiting	Phase 3	545	Eli Lilly and CompanyINDUSTRY	14	Jan 16, 2026	clinicaltrials
NCT00335816	Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer	active not recruiting	Phase 2	248	Memorial Sloan Kettering Cancer CenterOTHER	2	Jan 14, 2026	clinicaltrials
NCT04689347	5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	recruiting	Phase 1 / Phase 2	27	Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER	1	Jan 12, 2026	clinicaltrials
NCT06838338	JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC	active not recruiting	Phase 1	30	Jian LiOTHER	1	Jan 8, 2026	clinicaltrials
NCT05504252	METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2)	active not recruiting	Phase 2	80	University Hospital, AkershusOTHER	1	Jan 7, 2026	clinicaltrials
NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect)	active not recruiting	Phase 2	26	Emory UniversityOTHER	1	Jan 5, 2026	clinicaltrials
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 3	1,052	National Cancer Institute (NCI)NIH	3	Dec 30, 2025	clinicaltrials
NCT06512051	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer	recruiting	Phase 1 / Phase 2	248	Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY	1	Dec 23, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (24)

Drugs with predictive evidence (29)

Predictive evidence items (92)

Approvals mentioning the linked drugs (364)

Active trials (473)

Linked publications (85)